Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of NT-501 (CNTF) in Macular Telangiectasia Type 2
2017-003260-12Phase 3Completed
- Sponsor
- Neurotech Pharmaceuticals, Inc.
- Start
- Oct 2017
- Modality
- Cell Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of ciliary neurotrophic factor in macular telangiectasia type 2 (MacTel) (2 arms), sponsored by Neurotech Pharmaceuticals, Inc. Primary endpoint: Primary efficacy endpoint. Started Oct 2017; status: completed.
02
Drugs
ciliary neurotrophic factor
03
Conditions
macular telangiectasia type 2 (MacTel)
Beyond the preview
Go deeper on 2017-003260-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003260-12.